Previous 10 | Next 10 |
Portola Pharmaceuticals ( PTLA ) Q1 results : Revenues: $22.2M (+236.4%); Collaboration and license revenue: $1.8M (-70.0%). More news on: Portola Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Portola Pharmaceuticals (NASDAQ: PTLA ): Q1 Non-GAAP EPS of -$1.02 beats by $0.09 ; GAAP EPS of -$1.17 misses by $0.08 . More news on: Portola Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– First Quarter Revenues of $22.2 Million; Andexxa ® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya ® ; Staged Commercial Launch Planned in Second Half of 2019 – – Conf...
Portola Pharmaceuticals (NASDAQ: PTLA ) is scheduled to announce Q1 earnings results on Wednesday, May 8th, before market open. The consensus EPS Estimate is -$1.11 (+13.3% Y/Y) and the consensus Revenue Estimate is $20.6M (+212.1% Y/Y). Over the last 2 years, ptla has beaten EPS esti...
ACM , ANDX , ATHM , ATRO , BCOR , BG , BV , CBB , CBRE , CEIX , CFX , CHK , CORE , COTY , FOLD , FTDR , FUN , GCP , GOLD , GOLF , GTN , GTT , HMC , HZNP , ICPT , LXP , MCHP , MCK , MIDD , MPC , MPLX , MRNA , MSG , NXST , NYT , ODP , PFGC , PLUG , PTLA ...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
Portola Pharmaceuticals ( PTLA ) - The company announced that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa) to be used in adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed...
News, Short Squeeze, Breakout and More Instantly...
Portola Pharmaceuticals Inc. Company Name:
PTLA Stock Symbol:
NASDAQ Market:
Portola Pharmaceuticals Inc. Website:
SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and othe...
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagula...
SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to su...